Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop IPI-NIVO Trial
NL-OMON53859Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab and ipilimumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Ongoing response rate at 12 months. Started Jun 2023; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON53859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53859.